| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Omeprazole | FAERS: 5 | US FAERS | |
| 2 | Esomeprazole | FAERS: 2 | US FAERS | |
| 3 | Lansoprazole | FAERS: 2 | US FAERS | |
| 4 | Omeprazole | FAERS: 2 | US FAERS | |
| 5 | valdecoxib | FAERS: 2 | OFFSIDES US FAERS | |
| 6 | Atenolol | FAERS: 1 | US FAERS | |
| 7 | Clozapine | FAERS: 1 | US FAERS | |
| 8 | Loratadine | FAERS: 1 | US FAERS | |
| 9 | Moxifloxacin | FAERS: 1 | US FAERS | |
| 10 | Ranitidine | FAERS: 1 | US FAERS | |
| 11 | Terbinafine | FAERS: 1 | US FAERS | |
| 12 | Thyroxine | FAERS: 1 | US FAERS | |
| 13 | ledipasvir, sofosbuvir drug combination | FAERS: 1 | US FAERS | |
| 14 | palbociclib | FAERS: 1 | US FAERS | |
| 15 | Fluticasone | OFFSIDES | ||
| 16 | Lovastatin | Canada Vigilance: 1 | Canada Vigilance | |
| 17 | Paclitaxel | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.